Kenvue

Kenvue (KVUE) is a publicly traded company in the Consumer Staples sector, specifically within the Personal Care Products industry. Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026.

The company reports trailing twelve-month revenue of $3.91B and net income of $474.00M.

Key metrics include a return on equity of 4.5%, a debt-to-equity ratio of 1.53.

Investors tracking KVUE can follow price movements, analyst estimates, and fundamental changes directly through FINOTAUR's research tools.